A worldwide, Phase 3 clinical program evaluating etrasimod – an oral, selective, sphingosine 1 phosphate (S1P) receptor modulator – for the treatment of moderately to severely active ulcerative colitis.
Patients may be able to take part in the clinical program if they*:
- Are 16 to 80 years of age
- Were diagnosed with moderate to severe ulcerative colitis at least 3 months ago
- Did not respond to, are no longer responding to, or did not tolerate another UC therapy
*Other eligibility criteria may apply